Dr. Gregory Riely, MD, PhD
Claim this profileMemorial Sloan Kettering Cancer Center (All Protocol Activities)
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
2 reported clinical trials
5 drugs studied
Area of expertise
1Lung Cancer
Stage IV
ALK positive
EGFR positive
2Non-Small Cell Lung Cancer
Stage IV
ALK positive
EGFR positive
Affiliated Hospitals
Clinical Trials Gregory Riely, MD, PhD is currently running
Osimertinib + Chemotherapy
for Lung Cancer
This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osimertinib alone is the usual treatment for metastatic EGFR-mutant lung cancer. Researchers think adding chemotherapy to osimertinib could possibly add to the anticancer effects of the usual treatment and help stop cancer from growing or spreading.
Recruiting1 award Phase 29 criteria
Lorlatinib + Ramucirumab
for Lung Cancer
This study will test the safety of the combination of ramucirumab and lorlatinib. The researchers will test one or two different doses of lorlatinib in combination with ramucirumab to find the drug combination dose that causes few or mild side effects in participants. Once the researchers find this dose, they can test it in future participants to see if it is effective in treating their metastatic ALK-rearranged NSCLC. The researchers are also looking to see whether there are specific genes or DNA sequences associated with a response to treatment with lorlatinib and ramucirumab.
Recruiting1 award Phase 1 & 213 criteria
More about Gregory Riely, MD, PhD
Clinical Trial Related4 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Gregory Riely, MD, PhD has experience with
- Lorlatinib
- Ramucirumab
- Carboplatin
- Osimertinib
- Pemetrexed
Breakdown of trials Gregory Riely, MD, PhD has run
Non-Small Cell Lung Cancer
Chronic Conditions
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gregory Riely, MD, PhD specialize in?
Gregory Riely, MD, PhD focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are ALK positive.
Is Gregory Riely, MD, PhD currently recruiting for clinical trials?
Yes, Gregory Riely, MD, PhD is currently recruiting for 2 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Gregory Riely, MD, PhD has studied deeply?
Yes, Gregory Riely, MD, PhD has studied treatments such as Lorlatinib, Ramucirumab, Carboplatin.
What is the best way to schedule an appointment with Gregory Riely, MD, PhD?
Apply for one of the trials that Gregory Riely, MD, PhD is conducting.
What is the office address of Gregory Riely, MD, PhD?
The office of Gregory Riely, MD, PhD is located at: Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center (All Protocol Activities).
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.